2013 Annual Report
Read about the research we funded last year in our 2013 Annual Report.
SPRING 2015 - Join us for our cross-Canada stand-up comedy fundraising tour!
Cycle for Sight
JUNE 2015 - Join us for Cycle for Sight and enjoy the perfect one-day ride!
Ride for Sight
JUNE 2015 - Join us for Canada's biggest and longest-running motorcycle charity ride. The best party of the summer!
The Standards Program Trustmark is a mark of Imagine Canada used under licence by The Foundation Fighting Blindness.
News & Events
Vision Quest - Thank you!!
November 11, 2014 - Thank you to everyone who attended our 2014 Vision Quest series. Meeting with our community at Vision Quest inspires us to work harder every day!
Stem cell therapies are in the spotlight and everyone is watching the eye
October 29, 2014 - Learn about recent promising developments in two different clinical trials testing how stem cells can be used to fight blindness.
Spotlight on Stem Cells: Interview with Dr. Saeed Khalili, BMO Postdoctoral Fellow in Retinal Research
October 29, 2014 - Stem cell scientist, Dr. Khalili, shares his personal insights about the recent developments in stem cell therapeutics.
Harnessing the Power of Omega-3 Fatty Acids to Fight Age-Related Macular Degeneration
October 22, 2014 - A new Foundation-funded study shows that omega-3 fatty acid supplements can help wet AMD patients who are also receiving anti-VEGF injections.
Regenerative Medicine Milestone
October 16, 2014- Advanced Cell Technology (ACT), an early leader in the field of regenerative medicine, recently published data in The Lancet that shows positive results from its ongoing stem cell transplantation trial to treat Stargardt disease and dry age related macular degeneration.
Why do photoreceptors die? New discovery reveals important clues
October 15, 2014: Montréal - We need photoreceptors to see; without them, we have no way to sense light and the world becomes dark. Photoreceptor degeneration is shared by a variety of retinal diseases ranging from retinitis pigmentosa (RP) to age-related macular degeneration. Because of this, scientists are trying to regenerate lost photoreceptors. Dr. Michel Cayouette also wants to know what causes them to start dying in the first place. For Dr. Cayouette, understanding the mechanisms that underlie photoreceptor degeneration is the key to their ultimate protection.
$1 Million To Fight Blindness
October 14, 2014 - This year, Donna Green retired as Chair of the Foundation Fighting Blindness' Board of Directors, after 13 years of incredible leadership. In a remarkable show of support, Donna donated an extraordinary parting gift of $1 million to help sustain scientific momentum toward understanding, preserving and restoring vision.
A New Kind of Vision
October 14, 2014 - Today is a very exciting day at the Foundation Fighting Blindness because we are finally able to start sharing stories from the first Canadian patients to receive the Argus II implant, which used our valuable patient registry to identify the pioneering candidates: Orly Shamir and Ian Nichols.
Can stem cells be used to treat age-related macular degeneration?
September 17, 2014 - The world is watching after a woman in her 70s underwent a groundbreaking surgery in Japan.
Discovery paves the road for new treatments to prevent blindness in babies
An exciting new discovery by Foundation Fighting Blindness-funded scientist, Dr. Jean-Sébastien Joyal and colleagues, opens the door to new treatments for retinopathy of prematurity.
Love Your Eyes Contest Launch
September 9 , 2014 - This week, the Opticians Council of Canada launched their online Love Your Eyes contest. Until October 12, answer daily educational health puzzles for your chance to win big weekly prizes. The Foundation Fighting Blindness is proud to be this year's Love Your Eyes Title Sponsor.
Understanding the Link Between Protein Folding and Retinitis Pigmentosa
September 9, 2014 - Recognized as the "American Nobels," the Lasker Awards are a highly prestigious honor in medicine and science. This year, the Basic Medical Research recipients were honoured for their transformative studies of the cellular quality-control system: the unfolded protein response (UPR). Disruptions to UPR are thought to play a critical role in neurodegenerative diseases, including retinitis pigmentosa (RP).
Donor Survey: Prize Winners
This summer, the Foundation Fighting Blindness invited our entire community of supporters to provide feedback on our work and mission by completing an online survey. For participating, each person who responded was entered into a special prize draw for one of two, brand new KOBO e-readers. Find out if you or someone you know have won!
New Findings on an Eye Drop to Treat Wet Age-Related Macular Degeneration
August 28, 2014 - Investigators working with Ohr Pharmaceutical, Inc., in the United States have released new findings from their clinical trial of a topical (eye-drop) medication to treat wet age-related macular degeneration (AMD). These findings show that squalamine eye drops (referred to as OHR-102 by the company) may make current wet AMD treatments more effective, but the eye drops are unlikely to replace treatments by drug injections into the eye.
InVision Newsletter - Fall 2014
Watch your mailboxes for our latest InVision Newsletter or check it out online (PDF / DOC). In this issue, we showcase this year's new research grants, the results of the first oral medication trial to restore vision and the new Donna Green Award to Restore Sight.
MUHC researcher unveils novel treatment for a form of childhood blindness
July 13, 2014 — An international research project, led by the Research Institute of the McGill University Health Centre (RI-MUHC) in Montreal, reports that a new oral medication is showing significant progress in restoring vision to patients with Leber congenital amaurosis (LCA). Until now, this inherited retinal disease that causes visual impairment ranging from reduced vision to complete blindness, has remained untreatable. The study is published today in the scientific journal The Lancet.
Vision Quest 2014: Hope, Emerging Treatments & More
Our educational sessions are coming to a city near you! Registration is now open for Calgary, Hamilton & Toronto!
Eight New Sight-Saving Research Projects
June 17, 2014 - Could an experimental eye drop reverse the blinding effects of retinal disease in young children? Do drugs used to treat osteoporosis and heart disease have an effect on a person's risk of developing age-related macular degeneration? Can we turn on the retina's ability to repair itself? These are just a few of the questions being asked in the new research projects funded by the Foundation Fighting Blindness in 2014.
Update on the RPE65 Gene Therapy Trials
May 27, 2014 - Investigators estimate that this trial for one type of Leber congenital amaurosis is about two years from applying for approval in the USA. It will likely be the first gene therapy approved for an inherited retinal disease.
InSight Dinner Honours Volunteers, Supporters
May 12, 2014 - In April, 100 supporters gathered at our annual InSight Dinner in Toronto to celebrate 40 years of advancing eye research and public education.
World's Largest Vision Research Meeting Begins
May 4, 2014 - Scientists from around the world are meeting in Orlando for the annual Association for Vision Research and Ophthalmology conference. Commonly called ARVO, this annual conference is the predominant meeting for vision scientists each year, an opportunity to share new findings and discuss new ideas. We’ll be reporting on the conference over the next few days with news stories on important and intriguing presentations.
Trial of Treatment to Slow Retinitis Pigmentosa Vision Loss Begins in Italy
Apr 15, 2014 - The eye drop uses a nerve growth factor to protect photoreceptors is already being tested to treat another rare eye disease, neurotrophic keratitis.
Celebrating 40 Years of Discovery
April 2, 2014 - The Foundation Fighting Blindness has just released
Celebrating 40 Years of Discovery: Our Report to Donors. It tells the story of Foundation-funded research in Canada, its impact and influence globally, and how these discoveries are evolving into sight-saving therapies.
Accessible Media Inc. launches 2014 Scholarship Program
Apr 2, 2014 - The Foundation Fighting Blindness’ media partner, Accessible Media Inc., is launching a program to award two $5,000 scholarships per year to qualifying individuals, one of which is reserved for a student with a permanent disability.
Geneticist's Sight-Saving Contributions Recognized
Mar 31, 2014 - Dr. Jane Green’s pioneering research with Newfoundland and Labrador families has improved life for thousands of people with inherited retinal diseases - both inside and outside the province. This work has helped define and diagnose several eye diseases. Recently, she was honoured with the Order of Newfoundland and Labrador.
A Link between Exercise and Vision Health
Mar 25, 2014 - Scientists report the first clear evidence of a link between exercise and retinal health and vision.
Petition to Support Rare Disease Treatment
Mar 14, 2014 - Inherited retinal diseases like retinitis pigmentosa and Stargardt disease are rare diseases. Because they affect relatively small populations, the process of testing and approving drugs for rare diseases often needs to be different.
In Canada we don’t have a special framework to test and approve rare disease treatments, but we urgently need one. Right now, only 60% of treatments for rare disorders make it into Canada and most are approved much later than in the USA and Europe, where such frameworks exists. Few trials for rare diseases happen in Canada. A commitment to a Canadian framework was announced by Canada’s Health Minister in 2012, and our regulatory agency has drafted it, but it has still not been published or approved.
New Compound May be the Basis of a Promising Drug to Reverse Retinal Blindness
Feb 21, 2014 - California researchers invent a new "photoswitch," which may give light-sensing capacity to retinal nerve cells potentially restoring vision to people with advanced retinal degenerative diseases.
Dr. Bill Stell Reflects on the Foundation History of Sight-Saving Research
Feb 10, 2014 - For nearly 30 years, Dr. Bill Stell has volunteered his time and scientific expertise to help the Foundation Fighting Blindness select and fund scientific projects with the power to make a difference. We talked to him about how the science has changed over the past 40 years, and why he continues to be a passionate advocate for the Foundation.
Shorcan Brokers Ltd. donates over $10,000 to help vision research
Feb 11, 2013 - The 16th annual Shorcan Brokers Ltd. Charity Day raised a total of $10,827 for the Foundation Fighting Blindness. This is the 6th year Shorcan, TMX Group's fixed income interdealer brokerage, has supported the Foundation, bringing their total contribution to $61,362!
The unique one-day event contributed proceeds from the day's trading to select charities, among them the Foundation Fighting Blindness.
Testing the Safety of Induced Stem Cell Therapies
Feb 5, 2014 - Cells derived from induced pluipotent stem cells will soon be used in a clinical trial for dry age-related macular degeneration and may be used for other conditions as well. How are scientists addressing concerns about the potential cancer risk?
Forty years ago, Jay and Malca Marin applied to become a registered charity to fight blindness
Jan 20, 2014 - Forty years ago, Jay and Malca Marin applied to become a registered charity to fight blindness – and were rejected. But they didn’t give up. Instead, they dedicated their lives to creating the Foundation Fighting Blindness (then RP Foundation). Today, it’s Canada’s leading charity funding sight-saving research.
First gene therapy results for choroideremia suggest cautious optimism
Jan 16, 2014 - Results of the first six patients treated in the British gene therapy trial for choroideremia were released today. While many questions remain unanswered, the two most visually impaired participants experienced significant vision improvements. Canadian investigators at the University of Alberta will be able to build on these results, as the treatment of trial participants there will begin later this year.